Robert J T van der Leest1, Judith Zoutendijk2, Tamar Nijsten2, Wolter J Mooi3, Jasper I van der Rhee4, Esther de Vries5, Loes M Hollestein6. 1. Department of Dermatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands. Electronic address: r.vanderleest@erasmusmc.nl. 2. Department of Dermatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands. 3. Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands. 4. Department of Dermatology, LUMC University Medical Center, Leiden, The Netherlands; Department of Dermatology, Centrum Oosterwal, Alkmaar; Medisch Centrum Alkmaar, Alkmaar, The Netherlands. 5. Department of Dermatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands; Department of Public Health, Erasmus MC University Medical Center, Rotterdam, The Netherlands; National Cancer Institute, Directorate of Cancer Research, Surveillance, Prevention and Promotion, Bogotá, Colombia. 6. Department of Dermatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands; Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.
Abstract
BACKGROUND: A disproportional increase in in situ or thin melanomas may point at underlying causes such as increased melanoma awareness, as well as 'overdiagnosis' of melanoma in diagnostically equivocal small lesions. OBJECTIVES: The purposes of this study were to estimate trends in melanoma incidence by sex, Breslow thickness (thin melanomas subdivided into four subgroups: <0.25 mm, 0.25-0.49 mm, 0.50-0.74 mm, and 0.75-1.0 mm), age and location, and to compare these with trends in subgroups of thicker melanomas. METHODS: Data on all histologically confirmed in situ and invasive melanomas diagnosed between 1994 and 2010 were retrieved from the Netherlands Cancer Registry. Trends in European standardised rates (ESRs) were assessed using joinpoint analysis, and expressed as estimated annual percentage change (EAPC). RESULTS: Between 1994 and 2010, 34,156 persons were diagnosed with an in situ or thin melanoma. The ESR of in situ melanomas doubled for males and females with a recent steeper rise in incidence (EAPC 12% (95% confidence interval [CI]: 8.1-16) and 13% (95% CI: 5.9-20), respectively). ESR for thin melanomas amongst males approximately doubled with a steep, but non-significant acceleration compared to other thickness categories since 2006 for <0.25 mm melanomas (EAPC 26% (95% CI: 2.1-35)). For female patients with thin melanomas the ESRs increased almost two-fold, except for <0.25 mm melanomas. CONCLUSIONS: The incidence rates of in situ, thin and thick melanomas increased similarly between 1994 and 2010. Recently steep increases were found for in situ melanomas and thin melanomas in men. Explanations are 'overdiagnosis' in conjunction with increased ultraviolet exposure (natural and artificial) and therefore a 'true' increase, increased awareness, early detection, diagnostic drift and changed market forces in the Dutch health care system.
BACKGROUND: A disproportional increase in in situ or thin melanomas may point at underlying causes such as increased melanoma awareness, as well as 'overdiagnosis' of melanoma in diagnostically equivocal small lesions. OBJECTIVES: The purposes of this study were to estimate trends in melanoma incidence by sex, Breslow thickness (thin melanomas subdivided into four subgroups: <0.25 mm, 0.25-0.49 mm, 0.50-0.74 mm, and 0.75-1.0 mm), age and location, and to compare these with trends in subgroups of thicker melanomas. METHODS: Data on all histologically confirmed in situ and invasive melanomas diagnosed between 1994 and 2010 were retrieved from the Netherlands Cancer Registry. Trends in European standardised rates (ESRs) were assessed using joinpoint analysis, and expressed as estimated annual percentage change (EAPC). RESULTS: Between 1994 and 2010, 34,156 persons were diagnosed with an in situ or thin melanoma. The ESR of in situ melanomas doubled for males and females with a recent steeper rise in incidence (EAPC 12% (95% confidence interval [CI]: 8.1-16) and 13% (95% CI: 5.9-20), respectively). ESR for thin melanomas amongst males approximately doubled with a steep, but non-significant acceleration compared to other thickness categories since 2006 for <0.25 mm melanomas (EAPC 26% (95% CI: 2.1-35)). For female patients with thin melanomas the ESRs increased almost two-fold, except for <0.25 mm melanomas. CONCLUSIONS: The incidence rates of in situ, thin and thick melanomas increased similarly between 1994 and 2010. Recently steep increases were found for in situ melanomas and thin melanomas in men. Explanations are 'overdiagnosis' in conjunction with increased ultraviolet exposure (natural and artificial) and therefore a 'true' increase, increased awareness, early detection, diagnostic drift and changed market forces in the Dutch health care system.
Authors: Sara Rhaissa Rezende do Reis; Edward Helal-Neto; Aline Oliveira da Silva de Barros; Suyene Rocha Pinto; Filipe Leal Portilho; Luciana Betzler de Oliveira Siqueira; Luciana Magalhães Rebelo Alencar; Si Amar Dahoumane; Frank Alexis; Eduardo Ricci-Junior; Ralph Santos-Oliveira Journal: Pharm Res Date: 2021-02-18 Impact factor: 4.200
Authors: Bethan Clayton; Ferhan Muneeb; Maria Celia B Hughes; Megan E Grant; Kiarash Khosrotehrani; B Mark Smithers; Romina Spina; Luca G Campana; Deemesh Oudit; Adele C Green Journal: Int J Cancer Date: 2022-04-25 Impact factor: 7.316
Authors: Gundula Behrens; Tobias Niedermaier; Mark Berneburg; Daniela Schmid; Michael F Leitzmann Journal: PLoS One Date: 2018-10-31 Impact factor: 3.240